Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

McCain, 2014, Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options, Pharm Ther, 39, 130 James N, Sydes M. STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy, a multi-arm multi-stage randomised controlled trial. Protocol version 16. www.ctu.mrc.ac.uk/research/documents/cancer_protocols/STAMPEDE_protocol_v16.0. Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005 Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 58, 149, 10.1016/S1470-2045(12)70560-0 Fizazi, 2012, A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial, Eur J Cancer, 48, 209, 10.1016/j.ejca.2011.10.015 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 17, 243, 10.1016/S1470-2045(15)00489-1 Husereau, 2013, Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices task force, Value Health, 16, 231, 10.1016/j.jval.2013.02.002 James, 2016, Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer, Data from patients in the control arm of the STAMPEDE trial. JAMA Oncol, 2, 348 James, 2015, Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019), Eur Urol, 67, 1028, 10.1016/j.eururo.2014.09.032 James, 2016, Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). A multi-arm multi-stage randomised controlled trial, Protocol version, 15 Davis, 2014 Williams, 2016, Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial, Med Decis Making, 37, 340, 10.1177/0272989X16651869 Putter, 2011, Special issue about competing risks and multi-state models, J Stat Softw, 38, 1, 10.18637/jss.v038.i01 Putter, 2006, Estimation and prediction in a multi-state model for breast cancer, Biom J, 48, 366, 10.1002/bimj.200510218 Latimer, 2013, Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide, Med Decis Making, 33, 743, 10.1177/0272989X12472398 Afshar, 2015, Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience, Urol Oncol, 33, 10.1016/j.urolonc.2015.05.003 Dolan, 1997, Modeling valuations for EuroQol health states, Med Care, 35, 1095, 10.1097/00005650-199711000-00002 British National Formulary. www.evidence.nhs.uk/formulary/bnf/current. UK Government. Drugs and pharmaceutical electronic market information (eMit). www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit. Curtis, 2015 UK Government. NHS reference costs 2014 to 2015. Department of Health. www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015. Gillessen, 2018, Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, Eur Urol, 73, 178, 10.1016/j.eururo.2017.06.002 Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7 2013 Claxton, 2015, Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold, Health Technology Assessment, 19, 1, 10.3310/hta19140 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900 NHS England, 2016 National Institute for Health and Care Excellence, 2016 Ramsay, 2015, Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation, Health Technol Assess, 19, 1, 10.3310/hta19490 National Institute for Health and Care Excellence, 2016 Round, 2015, Estimating the cost of caring for people with cancer at the end of life: a modelling study, Palliat Med, 29, 899, 10.1177/0269216315595203